Connect with us

Legal & Regulation

Congressional Marijuana Employment Report Urges Government to Update Hiring and Firing Policies

Published

on

Congressional Marijuana Employment Report Urges Government to Update Hiring and Firing Policies

The House Appropriation Committee released a report attached to a spending bill, and therein, it recommended that the federal government reconsidering practices concerning hiring and firing related to marijuana compliance with state laws. The report also recommended a provision on protecting financial institutions servicing cannabis businesses.

The recommendation reads, in part:

“Hiring Guidelines—The Committee encourages OPM to review its policies and guidelines regarding hiring and firing of individuals who use marijuana in states where that individual’s private use of marijuana is not prohibited under the law of the State. These policies should reflect updated changes to the law on marijuana usage and clearly state the impact of marijuana usage on Federal employment.”

Currently, federal workers are prohibited from using marijuana, even if their states permit it. The recommendation will be considered by the Appropriations Committee this week. In addition to the above language in the recommendation, it also adds that a federal agency can only receive funds under the legislation if it “has in place, and will continue to administer in good faith, a written policy designed to ensure that all of its workplaces are free from the illegal use, possession, or distribution of controlled substances by the officers and employees of such department, agency, or instrumentality.”

Justin Strekal, NORML’s Political Director, shared with Marijuana Moment:

“We’re proud to support any efforts to ensure that the successful cannabis reform efforts in states around the nation are able to be implemented in smooth and sensible manner. “The prospect of responsible adults being denied federal employment opportunities is counterproductive and disproportionally impacts the veterans community. It is our hope that the final appropriations package maintain these provisions to give certainty to the increasing number of states that are ending the failed war on cannabis,” he said.

Concerning the provision related to financial institutions financing marijuana businesses, it reads in part, that none of the funds appropriated through the bill “may be used to penalize a financial institution solely because the institution provides financial services to an entity that is a manufacturer, a produce, or a person that participates in any business or organized activity that involves handling marijuana, marijuana products, or marijuana proceeds” in jurisdictions where marijuana is legal.

Kim or ‘KimD’ is an experienced, astute full-time writer with a Bachelor’s Degree in Literature. While her professional path is in Commercial Real Estate as an Accredited Buyer’s Representative and the financial industry, she loves to elaborate exclusively about CBD health and wellness information here at COR and will be around for a long time to come.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.